Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,434JPY
26 May 2017
Change (% chg)

¥-4 (-0.14%)
Prev Close
¥2,437
Open
¥2,446
Day's High
¥2,450
Day's Low
¥2,432
Volume
1,554,500
Avg. Vol
1,819,103
52-wk High
¥2,720
52-wk Low
¥2,192

Latest Key Developments (Source: Significant Developments)

Nektar says co may pay Daiichi $12.5 mln termination payment
Wednesday, 1 Jun 2016 08:23am EDT 

Nektar :In case of pre-conditional approval termination of deal, nektar would be obligated to pay daiichi a $12.5 million termination payment - sec filing.  Full Article

BRIEF-Nektar Therapeutics, Daiichi Sankyo Europe sign licensing deal for breast cancer drug
Wednesday, 1 Jun 2016 08:15am EDT 

Corrects to add dropped words in the second bullet.Nektar Therapeutics : Nektar Therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Nektar Therapeutics says also entitled to significant double-digit royalties on net sales in Europe . Plans to submit an MAA filing in June 2016 seeking conditional approval from EMA for use of Onzeald .Nektar Therapeutics and Daiichi Sankyo Europe GmbH sign European licensing agreement for Onzeald(TM) (Etirinotecan Pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

Nektar Therapeutics and Daiichi Sankyo Europe sign European licensing agreement for onzeald experimental treatment for breast cancer and brain metastases
Wednesday, 1 Jun 2016 08:15am EDT 

Nektar Therapeutics Says Also Entitled To Significant Double : Nektar therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments . Digit royalties on net sales in europe . Plans to submit an maa filing in june 2016 seeking conditional approval from ema for use of onzeald .Nektar therapeutics and daiichi sankyo europe gmbh sign european licensing agreement for onzeald(tm) (etirinotecan pegol), an investigational drug candidate being developed to treat patients with advanced breast cancer and brain metastases.  Full Article

Daiichi Sankyo provides update on HER3-lung study of patritumab in non-small cell lung cancer
Tuesday, 31 May 2016 08:30am EDT 

Daiichi Sankyo Co Ltd <4568.T> : Provides update on HER3-lung study of patritumab in non-small cell lung cancer (NCLC) . Two-Part phase 3 HER3-lung study of patritumab will not proceed into second part . Independent data monitoring committee concluded that first part of study (Part A) did not meet pre-defined efficacy criteria . Phase 2 study evaluating patritumab in previously-untreated recurrent, metastatic head, neck cancer is ongoing, enrolling patients .Decision followed recommendation of an independent data monitoring committee.  Full Article

Nitto signs partnership agreement with Daiichi Sankyo
Tuesday, 10 May 2016 09:00am EDT 

Nitto Denko Corp <6988.T> : Signed a partnership agreement with Daiichi Sankyo company, ltd. . Nitto will provide exclusive rights to passport system for an undisclosed compound owned by daiichi sankyo . Financial terms were not disclosed. .Will support clinical development of candidate in united states..  Full Article

R&I affirms Daiichi Sankyo's rating at "AA" and announces stable outlook
Thursday, 26 Nov 2015 01:00am EST 

Daiichi Sankyo Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA".Rating outlook stable.  Full Article

Daiichi Sankyo Co Ltd says will cut 1,000-1,200 jobs in U.S. - Reuters
Sunday, 18 Oct 2015 08:00pm EDT 

Daiichi Sankyo Co Ltd:The pharmaceutical company says it expects to cut 1,000-1,200 jobs in the United States - Reuters.Says will reorganise U.S. commercial organisation as it transitions from primary care product portfolio to differentiated specialty portfolio - Reuters.  Full Article

Daiichi Sankyo Co Ltd reorganizes its U.S. commercial operations to support upcoming specialty pipeline
Friday, 16 Oct 2015 11:11am EDT 

Daiichi Sankyo Co Ltd <4568.T>:Daiichi sankyo, inc. reorganizes its U.S. commercial operations to support upcoming specialty pipeline.Says company will reduce expenses, including a reduction in headcount, from its U.S. commercial operations.Says company expects to eliminate 1,000 to 1,200 positions across the U.S. commercial function.Says reorganization is not focused on U.S.-based research and development functions.Daiichi sankyo co - as part of reorganization, co will reduce expenses, including a reduction in headcount, from its U.S. commercial operations.Daiichi sankyo co -eliminated jobs will come from U.S. commercial home office, in Parsippany, new jersey,sales,other positions throughout country.To reorganize U.S. commercial organization as it transitions from primary care product portfolio to differentiated specialty portfolio.  Full Article

Daiichi Sankyo completes share repurchase
Tuesday, 25 Aug 2015 07:30pm EDT 

Daiichi Sankyo Co Ltd:Completes repurchase of 20,650,900 shares of its common stock, at the price of 49,999,930,971 yen in total, on Aug. 25.  Full Article

More From Around the Web

BRIEF-Daiichi Sankyo to invest 22 bln yen in U.S. for Luitpold Pharmaceuticals - Nikkei

* Daiichi Sankyo to invest 22 billion yen in U.S. for Luitpold Pharmaceuticals; targets about 70 pct rise in Luitpold's sales to 150 billion yen in fiscal 2020 versus 2015 - Nikkei Source (http://s.nikkei.com/2qhFwVe) Further company coverage: